Brian Wallach is a writer and advocate whose ALS diagnosis in 2017 redirected his career into systemic change for people with amyotrophic lateral sclerosis. Along with his wife, Sandra Fazekas, he founded the patient-led nonprofit I AM ALS and helped secure federal legislation and funding, while shaping public understanding of ALS and the patient experience. This profile explains who he is, how he responded to his diagnosis, what he has done to drive research and policy, and why his work remains influential for neurodegenerative disease advocacy.
Who is Brian Wallach
Brian Wallach built a career in journalism and nonprofit communication before symptoms of ALS prompted a rapid reassessment of his health and professional path. Diagnosed in 2017, he and his family confronted a disease with limited treatment options at the time, motivating a shift from reporting to direct action. Sandra Fazekas has been a central partner in this transition. Rather than treat his diagnosis as a personal endpoint, Wallach reframed it as a catalyst for systemic advocacy, leading public education, research acceleration, and policy reform efforts.
Early career and background
Before his diagnosis, Wallach worked as a journalist and in roles that relied on clarity of communication, evidence-based thinking, and stakeholder engagement. This background shaped his approach to advocacy, favoring transparency, rigorous sourcing, and measurable impact. He learned how to build coalitions, manage complex information, and communicate with policymakers, all of which became assets in the fight for ALS research and care infrastructure.
Diagnosis and early response
Receiving an ALS diagnosis in 2017 introduced urgent medical, emotional, and logistical questions. Wallach and Fazekas proceeded methodically, gathering specialist input, researching treatment landscapes, and documenting needs that were not being met by existing systems. Instead of waiting for institutions to act, they chose to channel personal insight into institutional change, creating a structured plan for public education, research support, and policy engagement.
Why advocacy became a focus
The scarcity of treatments and uneven access to specialized care revealed structural gaps in ALS services and research. Wallach recognized that a piecemeal response would not serve current or future patients. He and Fazekas committed to building durable infrastructure for advocacy, emphasizing patient-centered research standards, coordinated care models, and regulatory pathways that could accelerate therapies. The goal was to convert lived experience into leverage for systemic improvements.
Founding I AM ALS
I AM ALS emerged as a patient-led nonprofit designed to confront ALS as a public policy challenge, not only a medical issue. The organization built a research pipeline, convened stakeholders, and aligned legislative strategies to secure funding and regulatory support. Wallach’s role centered on framing advocacy in accessible, accountable language, while Fazekas helped ensure that family perspectives remained integral to strategy and outreach.
Legislative and policy achievements
Through coalition building and evidence-driven messaging, Wallach and his team contributed to meaningful policy outcomes. They helped pass legislation that expanded research funding, improved data collection, and coordinated federal resources around ALS. These achievements illustrate how patient leadership can convert personal urgency into durable public investment and accountability mechanisms.
Public education and awareness
Misunderstanding of ALS often leads to underestimation of its physical, emotional, and financial toll. Wallach committed to demystifying the disease through clear explanation, patient stories, and transparent accounts of what living with ALS entails. By prioritizing accuracy and empathy, he helped shift media portrayals and clinical expectations toward more realistic and humane models of care.
Reframing the patient narrative
Many portrayals of ALS focus only on loss of function, overlooking agency, adaptability, and social contribution. Wallach highlighted the continued value of people with ALS, emphasizing supported employment, communication strategies, and community involvement. This reframing informs both research priorities and policies related to employment, accessibility, and long-term support.
Media and outreach strategy
Wallach used platforms accessible to policymakers, clinicians, and the public to communicate the realities of ALS. Op-eds, interviews, and testimony were scheduled to coincide with legislative sessions or research milestones, maximizing the chance that evidence would inform decisions. His team coordinated with scientists, clinicians, and patients to ensure consistency between personal stories and scientific evidence.
Impact on research and care
By aligning advocacy with scientific rigor, Wallach helped create pipelines for research questions that reflect patient needs. This includes priorities around biomarkers, clinical trial design, coordination of care services, and reimbursement models that recognize the complexity of ALS. His work underscores how advocacy can bridge gaps between discovery, delivery, and everyday lived experience.
Research acceleration and funding
Through policy engagement and coalition leadership, Wallach contributed to increased federal funding for ALS research. This included support for registries, natural history studies, and trials that incorporate patient-reported outcomes. The emphasis is on therapies that meaningfully change trajectories of daily living, not only on surrogate markers.
Care models and accessibility
Systematic barriers around scheduling, transportation, specialist access, and assistive technology often limit care quality. Wallach’s advocacy pressed for coordinated service networks, telehealth where appropriate, and standardized competencies for clinicians. The aim is to ensure that innovations in treatment reach people with diverse incomes, locations, and support structures.
How ALS advocacy has evolved
Advocacy around ALS has shifted from emergency fundraising toward sustained policy engagement, data infrastructure, and research governance. This evolution reflects lessons learned from earlier efforts that focused on awareness without clear mechanisms for translating attention into services. Wallach has helped anchor I AM ALS within this more mature landscape, balancing urgency with long-term planning.
Current strategic priorities
Present efforts focus on closing gaps in diagnosis delays, diversifying trial participation, and embedding patient priorities in regulatory guidance. There is also attention to workforce training, reimbursement reform, and integration of mental health and palliative services. These priorities aim to improve both survival time and quality of life for people with ALS.
Future vision and sustainability
Durable change requires stable funding, transparent metrics, and accountability to people with ALS and their caregivers. Wallach has emphasized building structures that survive election cycles and scientific shifts, ensuring that advocacy remains effective even as leadership or priorities evolve. Sustainability, equity, and measurable outcomes are central to this vision.
Verified facts and key details
Wallach cofounded I AM ALS, helped secure federal ALS research and care legislation, and shaped national understanding of the disease through patient-centered storytelling. The following table summarizes selected, verifiable attributes and milestones related to his advocacy timeline and impact.
Fact summary table
| Attribute | Verified Detail | Source Type |
|---|---|---|
| Diagnosis year | 2017 | Reported in patient interviews and I AM ALS materials |
| Organization founded | I AM ALS | Nonprofit registry and press releases |
| Legislative influence | Support for federal ALS research and care policies | Congressional records, advocacy summaries |
| Primary role | Co-founder and advocate | Organization leadership pages, media profiles |
| Family partner | Sandra Fazekas | Joint interviews and organizational disclosures |
Comparative framing
Compared with general awareness campaigns, Wallach’s model emphasizes policy infrastructure and research alignment with patient priorities. Compared with medical-only advocacy, his approach integrates lived experience, media strategy, and legislative drafting. The table below contrasts these dimensions to clarify the distinctiveness of his work.
Approach comparison
| Approach | Emphasis | Outcome |
|---|---|---|
| General awareness campaigns | Broad recognition | Increased public familiarity, limited policy change |
| Medical-only advocacy | Therapy development | Progress in trials, gaps in care and access |
| Patient-led systems advocacy | Policy, care infrastructure, research priorities | Coordinated funding, regulatory alignment, improved service pathways |
Status and outlook
As of the current date, Wallach remains active in I AM ALS and related initiatives, with continued focus on legislative engagement, research acceleration, and equitable care. New therapies and ongoing trials reflect the momentum built through advocacy, though access and implementation challenges persist. His near-term priorities include faster diagnosis, broader trial inclusivity, and sustainable funding; longer-term goals involve embedding patient voices in governance and evaluation of outcomes across the care continuum.
Outlook summary
- Continued legislative and regulatory engagement at federal and state levels
- Support for research infrastructure that centers patient priorities and real-world outcomes
- Expansion of coordinated care networks and telehealth to reduce access barriers
- Commitment to transparent metrics and accountability to the ALS community
Tags
ALS advocacy, I AM ALS, patient-led advocacy, neurodegenerative disease policy, Brian Wallach